Compare Merck & Co., Inc. (MRK) vs ThredUp Inc (TDUP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ThredUp Inc — how do they compare? Merck & Co., Inc. trades at $133.9 (market cap $327.94B), while ThredUp Inc trades at $3.13 (market cap $405.82M). The key difference: Merck & Co., Inc. is far larger — about 808.1× ThredUp Inc's market cap, and Merck & Co., Inc. pays a 2.56% dividend while ThredUp Inc pays none. Which is the better fit depends on your goals.
| MRK | TDUP | |
|---|---|---|
Market Cap | $327.94B | $405.82M |
Sector | Health | Consumer Cyclical |
52-Week High | $132.93 | $12.08 |
52-Week Low | $77.60 | $3.08 |
Enterprise Value | $374.70B | $404.00M |
Dividend Yield | 2.56% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $133.30, up 2.18% today, with a bullish technical signal and strong institutional buying interest. Recent earnings beats and the acquisition of Terns Pharmaceuticals for $6.7 billion highlight strategic growth in oncology. The stock shows robust cash flow from operations of $16.47 billion in 2025 and a consensus price target of $140.58, indicating potential upside.
Outlook remains positive with analyst consensus at 67.57% buy ratings, though risks include high P/E of 106.34 and net income margin volatility. The acquisition expands Merck's pipeline but integration execution is key. Dividend yield supports income investors, while valuation metrics suggest careful monitoring of earnings growth sustainability.
ThredUp (TDUP) trades at $3.08, down 4.64% amid a bearish technical signal. The company reported Q2 2026 revenue growth of 16.9% to $90.8 million but missed EPS estimates and cut full-year revenue guidance, triggering a sharp stock decline. Despite a high gross margin of 79.52%, the firm remains unprofitable with a net income margin of -6.65%. Analyst consensus is positive with 57% buy ratings, but recent news highlights shareholder investigations and promotional headwinds.
The outlook is clouded by near-term execution risks and persistent losses, though long-term potential exists if the company can leverage its asset-light model and AI tools to achieve profitability. Key risks include competitive pressures, macroeconomic sensitivity, and the need to improve cost management. Investors should weigh analyst optimism against the company's challenging path to sustained earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ThredUp Inc
ThredUp Inc is an online resale platform for women and kids apparel, shoes, and accessories. It generates revenue from items that are sold to buyers through the website, mobile app, and RaaS partners.
Read more on TDUP →
